ClinicalTrials.gov record
Completed Phase 2 Interventional

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

ClinicalTrials.gov ID: NCT05326412

Public ClinicalTrials.gov record NCT05326412. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study identification

NCT ID
NCT05326412
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sanofi
Industry
Enrollment
49 participants

Conditions and interventions

Interventions

  • Itepekimab SAR440340 Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 18, 2022
Primary completion
Mar 4, 2025
Completion
Jul 24, 2025
Last update posted
Mar 10, 2026

2022 – 2025

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
UCLA Medical Center - Harbor- Site Number : 8400006 Torrance California 90509
National Jewish Health Medical Center- Site Number : 8400012 Denver Colorado 80206
University of Miami UHealth Tower- Site Number : 8400015 Miami Florida 33125
Harvard Medical School - Massachusetts General Hospital (MGH) - Medical Practice Evaluation Center (MPEC)- Site Number : 8400007 Boston Massachusetts 02114
Pulmonary and Medicine Associates- Site Number : 8400020 Warren Michigan 48088
University of Kansas Medical Center- Site Number : 8400004 Kansas City Missouri 66160
Allergy, Asthma and Clinical Research- Site Number : 8400010 Oklahoma City Oklahoma 73120
Clinical Research Associates of Central PA - Dubois- Site Number : 8400011 DuBois Pennsylvania 15801
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400016 Philadelphia Pennsylvania 19104
University of Texas - Southwestern Medical Center- Site Number : 8400014 Dallas Texas 75390
University of Texas Medical Branch- Site Number : 8400001 Galveston Texas 77555

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05326412, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 10, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05326412 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →